Lupin Limited
Financial trend (100/100) does the heavy lifting; momentum (24/100) is the drag.
Buy zoneOur blended model reads Lupin Limited as a Strong Buy at 76/100. At ₹2,095 it trades below our blended DCF and relative-multiples fair value of ₹3,463.11, about 65% upside to that estimate — we read it as undervalued by 65%. On 20.3x trailing earnings it sits cheaper than the Healthcare median of about 37.6x. The price is about 17% below its 52-week high of ₹2,514.8 and 11% above the low of ₹1,891.88. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 6/9. The average analyst target of ₹2,466.51 implies about 18% upside across 37 analysts. It clears 10 of 13 investability checks, with durability 85, valuation 74 and momentum 24 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹2,770.49.
Analyst views
1-year price
EOD · 2026-09-1452-week range
-16.69% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Strong Buy76Piotroski F-score 6/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Pass: ROE above 15%: 26.9%
- Pass: Low debt (D/E < 0.5): 0.29x
- Pass: Positive free cash flow
- Pass: Revenue growth > 10%: 32%
- Pass: Earnings growing: 89%
- Pass: Net margin ≥ 10%: 19.1%
- Pass: Current ratio > 1.5: 1.90
- Pass: Below our fair value
- Pass: Margin of safety ≥ 20%
- Fail: Above 200-day average
- Fail: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 5.7
- Fail: Piotroski ≥ 7: 6/9
Quarterly results
Annual financials
Shareholding
- Promoter47.0%
- Institutions34.6%
- Public & other18.4%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Strong return on equity (26.9%).
- Lightly leveraged balance sheet.
- Healthy profit margin (19.1%).
- Financially solid — Altman Z 5.7.
Opportunities
- Earnings growing (89% YoY).
- Revenue growing (32% YoY).
- Trading in our value buy zone versus sector peers.
- Trades ~65% below our estimated fair value.
Bear case
Weaknesses
- Price below its 200-day moving average (downtrend).
About Lupin Limited
Lupin Limited is a pharmaceutical company operating in India, the United States, and internationally through two segments: Pharmaceuticals and Others. The company discovers, develops, produces, and markets branded and generic formulations, biosimilars, over-the-counter drugs, specialty drugs, and active pharmaceutical ingredients.
Lupin Limited — frequently asked questions
Is Lupin Limited a buy, hold or sell?
StocksWizard currently rates Lupin Limited (LUPIN) a Strong Buy, based on a blended score of 76/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Lupin Limited's fair value?
Our blended DCF and relative-valuation model estimates Lupin Limited's fair value at about ₹3,463.11, versus a current price of ₹2,095 — roughly 65% upside. On that basis the stock looks undervalued by 65%.
Is Lupin Limited financially healthy?
Lupin Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 6/9.
How has Lupin Limited's share price performed?
Lupin Limited is down 7% over three months, and last traded at ₹2,095. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.